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NLRP3-inflammasome activates caspase-1 and processes pro-IL-1b and pro-IL-18 into the active cytokines.
Two recent studies describe specific inhibitors of NLRP3 inflammasome that inhibit IL-1b release and inflam-
mation. The specificity and potency of these compounds gives hope that a targeted approach to inhibit
NLRP3-driven inflammation may be just around the corner.Activation of some of themost biologically
activemembers of the IL-1 family, such as
IL-1b or IL-18, is dependent on the cleav-
age of inactive precursors. This process is
mediated by activation of protein plat-
forms called inflammasomes that activate
inflammatory caspases that in turn lead to
cleavage and activation of IL-1b and IL-18
(Lamkanfi and Dixit, 2014). ‘‘Classical’’
(or ‘‘canonical’’) inflammasomes activate
caspase-1, while ‘‘non-canonical’’ inflam-
masomes activate caspase-11. Inflam-
masomes include either receptors of the
NOD-like receptor (NLR) family of proteins
(e.g., NLRP3, NLRP1, and NLRC4) or AIM
receptors (AIM2 inflammasome) (Lam-
kanfi and Dixit, 2014). Specific inhibition
may give the opportunity for targeted
therapy in particular diseases in which
each of these inflammasome complexes
are involved in pathogenesis. While
endogenous inhibitors of inflammasome
such as IL-37 or type I interferons are
well known, very few pharmacological
inhibitors that can be used in the patients
have been described to date (Ahn et al.,
2014; Juliana et al., 2010). Moreover,
these pharmacological inhibitors are
relatively non-specific and have low effec-
tiveness. Due to these limitations, broad
blockade with anti-IL-1b antibodies or re-
combinant IL-1 receptor antagonist rep-
resents the mainstay of anti-IL-1 therapy
to date. In addition, no anti-IL-18 treat-
ment is currently available.
An important step toward the goal
of targeted anti-IL-1/IL-18 therapy was
made by two studies published recently
in Nature Medicine (Coll et al., 2015;
Youm et al., 2015). Changes in the meta-
bolic processes during specific ketogenic
diet or starvation lead to the use of alter-
native sources of energy. In periods char-
acterized by glucose shortage, ketonebodies have been shown to enter meta-
bolic pathways and to be used as an alter-
native ATP source. In a recent study inNa-
tureMedicine, Youm et al. (2015) reported
that the ketone body b-hydroxybutyrate
(BHB) specifically inhibits NLRP3 inflam-
masome activation and the production
of active IL-1b and IL-18. This effect led
to inhibition of these proinflammatory
cytokines by several well-known NLRP3
activators both in mouse bone-marrow-
derived macrophages and human mono-
cytes. In addition, when administered
in vivo in formulations containing nanolip-
ogens aimed to improve its bioavailability,
BHB inhibited NLRP3 inflammasome acti-
vation in response to monosodium ureate
(MSU) crystals, the causative agent of
gout. In contrast, no effect on the activa-
tion of NLRP1, NLRC4, or AIM2 inflamma-
some has been observed. Similarly, in
mouse models mirroring the human
gain-of-function mutations in NLRP3 that
lead to the auto-inflammatory syndromes
Muckle-Wells (MWS) and familial cold
auto-inflammatory syndrome (FCAS),
BHB induced by a ketogenic diet potently
reduced IL-1b secretion and peritoneal
inflammation (Youm et al., 2015).
The study of Youm and colleagues is
a novel argument for the strong interac-
tion between metabolic processes and
immune stimulation. Increasing amounts
of evidence point toward a crucial
role for cellular metabolism of glucose
during the monocyte/macrophage, den-
dritic cell, and lymphocyte activation,
with oxidative phosphorylation being the
main pathway being used by naive or
tolerant cells, while cellular metabolism
shifts toward aerobic glycolysis during
activation—the so-called Warburg effect
(Tannahill et al., 2013). In addition, a
recent report showed that fatty acid syn-Cell Metabolismthesis is a strong inducer of NLRP3 acti-
vation, suggesting that this may represent
another target for anti-inflammatory
therapy (Moon et al., 2015). Interestingly,
the metabolites acetoacetate or butyrate,
which are structurally related to BHB, did
not inhibit activation of the inflamma-
some, although they have been previously
shown to have important anti-inflamma-
tory properties (Vinolo et al., 2011).
A different approach was initiated by
Coll et al. (2015) who report identification
of a synthetic NLRP3 inhibitor of the in-
flammasome that they termed MCC950.
Interestingly, this compound has been
previously described as an inhibitor of
IL-1b, but its effects on the inflammasome
activation were not known. MCC950
blocked NLRP3 activation in both in vitro
mouse macrophage stimulation as well
as in vivo experimental models such as
endotoxemia and a mouse model of mul-
tiple sclerosis. Similar to Youm and col-
leagues, Coll et al. (2015) also showed
MCC950 to ameliorate the symptoms of
MWS in a mouse model. Even more
importantly, blockade of NLRP3 activa-
tion by MCC950 led to inhibition of IL-1b
production by leukocytes isolated from
patients with MWS.
The mechanisms through which BHB
and MCC950 inhibit NLRP3 activation
differ. BHB inhibits the K+ efflux and ASC
oligomerization, while MCC950 does not.
Interestingly, and in contrast to BHB,
which only inhibited activated caspase-1,
MCC950 inhibits both canonical caspase-
1 activation and the non-canonical cas-
pase-11 pathway of IL-1b activation and
pyroptosis induction (Coll et al., 2015)
(Figure 1). This differential effect opens
the possibility to specifically approach the
treatmentofconditions inwhicheithercap-
sase-1 and/or caspase-11 are involved.21, April 7, 2015 ª2015 Elsevier Inc. 513
Figure 1. Schematic Illustration of the Molecular Mechanisms of NLRP3 Activation and the
Targets of b-hydroxybutyrate and the Pharmacologic Inhibitor MCC950
NLRP3 inflammasome is activated by MSU, ATP, or lipotoxic fatty acids. Caspase-1 processes intracel-
lular pro-IL-1b and pro-IL-18 into the active cytokines. K+ efflux is needed for optimal inflammasome
activation. BHB inhibits the efflux of K+, while both BHB and MCC950 inhibit ASC oligomerization and
speck formation. Interestingly, MCC950 inhibits both caspase-1 and caspase-11, while BHB only affects
caspase-1 activation.
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PreviewsWhile the two studies are very important
steps toward the aimof specific inflamma-
some-dependent therapy, important chal-
lenges remain. While the specific effect of
NLRP3 inhibition gives hope that IL-1 inhi-
bition will be selective and probably not
complete, thus sparing the activation of
other inflammasomes (e.g., NLRC4 and
AIM2 inflammasomes) involved in host
defense, this should be formally tested in
infection models. Moreover, one should
also test the possible effects of these
inhibitors in infection models in which
NLRP3 inflammasome does play a role,
such as disseminated candidiasis (Gross514 Cell Metabolism 21, April 7, 2015 ª2015et al., 2009). In addition, one should
consider the most likely inflammatory dis-
eases in which NLRP3 inflammasome
plays a role and in which these com-
pounds are likely to be effective, espe-
cially taking into account the known
inflammasome-independent processing
of pro-IL-1b by neutrophil-derived serine
proteases. Thus, while monocyte/macro-
phage-dependent inflammatory pro-
cesses are likely to react to the novel
NLRP3 inhibitors, this is less likely to
happen inmodels of inflammation inwhich
neutrophils play a major role. One such
condition is gout (Joosten et al., 2010),Elsevier Inc.and testing the effectiveness of these
compounds in experimental models of
gout mimicking human disease by intra-
articular injection of uric acid crystals is
warranted.
To conclude, the two important studies
by Youm et al. (2015) and Coll et al. (2015)
open a new chapter in our anti-inflamma-
tory therapeutic armamentarium in which
NLRP3-specific inhibition should have an
important place.REFERENCES
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